Highlights Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Real-time Estimate Cboe BZX Other stock markets 13:50:51 2024-05-14 EDT			5-day change	1st Jan Change
40.43 ^USD	+0.57%		+3.05%	-11.79%

05-08	BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49	MT
05-07	Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell	05-07	MT
Earnings Flash (RYTM) RHYTHM PHARMACEUTICALS Reports Q1 Revenue $26M, vs. Street Est of $26.9M	05-07	MT
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting	05-06	CI
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology	04-29	CI
Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock	04-01	MT
Rhythm Pharmaceuticals Doses First Patients in Phase 1 Trial of Potential Obesity Therapy	03-25	MT
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	03-25	CI
Rhythm Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises; Shares Down Pre-Bell	02-22	MT
Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan	02-22	CI
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome	02-07	CI
Rhythm Pharmaceuticals, Inc. Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates	01-04	CI
Rhythm Pharmaceuticals Says Setmelanotide Phase 3 Trial in Children Meets Primary Goal	12-06	MT
Rhythm Pharmaceuticals' Shares Fall After Q3 Net Loss Narrows, Higher Revenue Beats Forecasts	11-07	MT
Earnings Flash (RYTM) RHYTHM PHARMACEUTICALS Reports Q3 Revenue $22.5M, vs. Street Est of $22.2M	11-07	MT
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)	11-02	CI
Rhythm Pharmaceuticals Says EU Regulator Endorses Orphan Drug Designation for Acquired Hypothalamic Obesity Treatment	23-09-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Highlights

Filters